Patent: 9,260,724
✉ Email this page to a colleague
Summary for Patent: 9,260,724
Title: | Optimization of expression of parvoviral rep and cap proteins in insect cells |
Abstract: | The present invention relates to the improved production of recombinant parvoviral virions in insect cells. In particular, the invention relates to an improved process for the production of recombinant parvoviral virions in insect cells, wherein the full/empty parvoviral virion ratio is increased. The invention also relates to the production of parvoviral vectors that may be used in gene therapy and to improvements in expression of the viral Rep proteins that increase the productivity of parvoviral vectors. |
Inventor(s): | Bakker; Andrew Christian (Almere, NL), Hermens; Wilhelmus Theodorus Johannes Maria Christiaan Maria Christ (Almere, NL), Noordman; Yvet (Utrecht, NL) |
Assignee: | UNIQURE IP B.V. (Amsterdam, NL) |
Application Number: | 14/149,953 |
Patent Claims: | see list of patent claims |
Details for Patent 9,260,724
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2028-02-19 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2028-02-19 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2028-02-19 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |